| Item 2.02 | Results of Operations and Financial Condition. |
On October 10, 2023, Pulmonx Corporation (the “Company”) issued a press release announcing its preliminary unaudited revenue results for the third fiscal quarter ended September 30, 2023. A copy of the Company’s press release dated October 10, 2023 titled “Pulmonx Announces CFO Transition and Record Preliminary Third Quarter 2023 Revenue” is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The foregoing information (including the exhibit hereto) is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Departure of Chief Financial Officer
On October 6, 2023, Derrick Sung, Ph.D., Chief Financial Officer of the Company, stepped down from his position, effective October 10, 2023 (the “Effective Date”), to pursue a new business opportunity. Dr. Sung’s resignation was not due to any disagreement with the Company on any matter, including related to the Company’s operations, policies, practices, financial reporting, or internal controls. In connection with Dr. Sung’s resignation as Chief Financial Officer, John McKune, Vice President, Corporate Controller of the Company, was appointed by the Board of Directors of the Company (the “Board”) to serve as the Interim Chief Financial Officer of the Company, effective as of the Effective Date.
To facilitate a smooth transition as the Board conducts a search for a permanent Chief Financial Officer, Dr. Sung will remain an employee of the Company in an advisory role to the Company’s executive leadership team through October 31, 2023 (the “Separation Date”). In connection with Dr. Sung’s departure from the Company, the Company and Dr. Sung entered into a Consulting Agreement (the “Consulting Agreement”), effective as of November 1, 2023. The Consulting Agreement provides for, among other things, (i) a consulting arrangement whereby Dr. Sung will provide certain consulting services to the Company through March 2, 2024, unless terminated earlier pursuant to the terms of the Consulting Agreement (the “Consulting Period”), and (ii) continued vesting through the Consulting Period of each outstanding equity award held by Dr. Sung as of the Separation Date.
The foregoing description of the Consulting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Consulting Agreement, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023.
Appointment of Interim Chief Financial Officer
Prior to Mr. McKune’s appointment as Interim Chief Financial Officer of the Company, Mr. McKune, age 48, has served as Vice President, Corporate Controller of the Company since joining the Company in August 2020, and Mr. McKune will continue in this role in addition to serving as Interim Chief Financial Officer. Prior to joining the Company, Mr. McKune served as Vice President, Corporate Controller at Accuray Incorporated, a radiation therapy company, from September 2017 to August 2020. From August 2015 to March 2017, Mr. McKune served as Vice President, Finance and Principal Accounting Officer of Carbylan Therapeutics. From January 2014 to July 2015, Mr. McKune served as Corporate Controller for View Inc., a manufacturer of dynamic glass. From April 2012 to August 2013, Mr. McKune served as Corporate Controller of Conceptus, Inc., which was acquired by Bayer Healthcare. Mr. McKune began his career in public accounting, holding positions of increasing responsibility, most recently serving as an audit manager at PricewaterhouseCoopers, LLP. Mr. McKune holds a B.S. in Accounting from Brigham Young University and has been a California-licensed certified public accountant since 2005.
1
